<h4>Introduction</h4><i>KRAS G12C</i> mutations define a molecularly distinct subset of NSCLC for which targeted therapy with sotorasib has exhibited clinical efficacy. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.